A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548

What is the purpose of this trial?

The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving temozolomide plus radiation therapy compared with patients receiving nivolumab in addition to temozolomide plus radiation therapy.



Bristol-Myers Squibb Company

Start Date: 09/22/2016

End Date: 05/01/2018

Last Updated: 02/22/2018

Study HIC#: 1604017530

Get Involved

For more information about this study, contact:
Tenzin Choezom
+1 203-785-3865
t.choezom@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Joachim M Baehring

Principal Investigator

Sub-Investigators